Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,157Revenue $M0.0Net Margin (%)0Z-Score-10.4
Enterprise Value $M2,302EPS $-0.6Operating Margin %0F-Score4
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yY
Price/Book010-y EBITDA Growth Rate %-18.8Quick Ratio0.4Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-26.5Current Ratio0.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-94.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M402ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with MNKD

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MNKDJean-Marie Eveillard 2013-03-31 Sold Out -0.01%$2.31 - $3.56
($2.75)
$ 5.3695%Sold Out0
MNKDJean-Marie Eveillard 2012-12-31 Buy 0.01%$1.85 - $2.83
($2.16)
$ 5.36148%New holding, 800000 sh.800,000
MNKDGeorge Soros 2007-09-30 Sold Out -0.01%$8.87 - $13.09
($10.2)
$ 5.36-48%Sold Out0
MNKDGeorge Soros 2007-06-30 Buy 0.01%$11.46 - $14.95
($13.3)
$ 5.36-60%New holding, 13493 sh.13,493
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MNKD is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


MNKD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Martens JuergenCorporate VP 2014-10-03Sell63,800$5.48-2.19 view
Martens JuergenCorporate VP 2014-08-27Sell417$7.6-29.47 view
Martens JuergenCorporate VP 2014-08-22Sell22,775$7.02-23.65 view
Palumbo DianeVice President, Human Resource 2014-08-15Sell18,726$7.01-23.54 view
Thomson DavidVP & General Counsel 2014-08-07Sell30,000$8.16-34.31 view
Martens JuergenCorporate VP 2014-07-28Sell416$8.55-37.31 view
Martens JuergenCorporate VP 2014-07-21Sell26,458$9.65-44.46 view
Thomson DavidVP & General Counsel 2014-07-17Sell30,000$9.42-43.1 view
Palumbo DianeVice President, Human Resource 2014-07-15Sell17,901$10.01-46.45 view
PFEFFER MATTHEW JCorporate VP and CFO 2014-07-01Sell20,000$10.44-48.66 view

Press Releases about MNKD :

    Quarterly/Annual Reports about MNKD:

    News about MNKD:

    Articles On GuruFocus.com
    Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
    How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
    Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
    Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
    There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 
    What This Upcoming Monday Means For MannKind Shareholders Aug 08 2014 
    Shareholders To Inhale Relief As MannKind Found Its Bright Insulin Supply Partner Amphastar Aug 06 2014 
    Shareholders To Inhale Relief As MannKind Found Its Bright Insulin Supply Partner Amphastar Aug 06 2014 
    Osiris Stem Cells To Compliment Mannkind's Afrezza In Disrupting Diabetes Market Jul 29 2014 
    Mannkind Corporation: Safe Labeling, Incentivized Spirometry and Experts Votes of Confidence Jul 25 2014 

    More From Other Websites
    Goldman Sachs Analyst Neutral Rating of MannKind Feels Like Downgrade Oct 20 2014
    MannKind: Goldman Sachs Sees 'Limited Upside' Oct 20 2014
    MannKind (MNKD) Worth Watching: Stock Gains 12.9% Oct 16 2014
    Short Interest in Biotech Becomes Company Specific Oct 10 2014
    MannKind Receives $150 Million Upfront Payment from Sanofi Oct 03 2014
    MannKind Announces Receipt of $150 Million Licensing Upfront Payment Sep 29 2014
    MANNKIND CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Sep 29 2014
    The Zacks Analyst Blog Highlights: Con-way, Covenant Transportation Group, Old Dominion Freight... Sep 29 2014
    MannKind and Sanofi Complete Afrezza Collaboration Deal Sep 26 2014
    [video] Stocks Start the Day Lower as Investors Assess Latest Economic Data Sep 25 2014
    US STOCKS-MannKind, Magnum Hunter among premarket actives Sep 25 2014
    MANNKIND CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 24 2014
    MannKind Announces Closing of Global Licensing Agreement With Sanofi Sep 24 2014
    Why You Shouldn't Bet Against MannKind (MNKD) Stock Sep 18 2014
    MannKind Corporation to Present at Morgan Stanley Global Healthcare Conference Sep 02 2014
    MannKind: Why Jefferies Says Buy Aug 27 2014
    How Will MannKind (MNKD) Stock Respond to This Coverage Initiation? Aug 27 2014
    Roche Buying InterMune for $8.3 Billion; Investors Want More Pharma Deals Aug 25 2014
    Who's Next in the M&A Wave Aug 22 2014
    MANNKIND CORP Financials Aug 19 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK